Shenzhen Geno-Immune Medical Institute

Country

Ownership: Private

Established: 2015-04-28

Employees: -

Market Cap: -

Website

Clinical Trials

Targeting CD276 (B7-H3) Positive Solid Tumors by 4SCAR-276

Phase 1

Conditions: Solid Tumor

Interventions: Biological: 4SCAR-276

First Posted Date: 2020-06-16

Last Posted Date: 2020-06-16

Lead Sponsor: Shenzhen Geno-Immune Medical Institute

Target Recruit Count: 100

Registration Number: NCT04432649

Locations: 🇨🇳
Shenzhen Children's Hospital, Shenzhen, Guangdong, China
🇨🇳
Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China
🇨🇳
Sun Yat-Sen University, Shenzhen, Guangdong, China

PSMA-specific CAR-T Cell Therapy

Phase 1

Recruiting

Conditions: PSMA Positive Tumors or Tumor Tissues

Interventions: Biological: 4SCAR-PSMA T cells

First Posted Date: 2020-06-12

Last Posted Date: 2020-06-12

Lead Sponsor: Shenzhen Geno-Immune Medical Institute

Target Recruit Count: 100

Registration Number: NCT04429451

Locations: 🇨🇳
Shenzhen Children's Hospital, Shenzhen, Guangdong, China
🇨🇳
Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China
🇨🇳
Shenzhen Hospital of Southern Medical University, Shenzhen, Guangdong, China

and more 1 locations

Multi-CAR-T Cells Targeting B Cell Lymphomas

Phase 1

Conditions: B Cell Lymphoma (BCL)

Interventions: Biological: 4SCAR19 and 4SCAR20/22/70/PSMA/13/79b/GD2

First Posted Date: 2020-06-12

Last Posted Date: 2020-06-12

Lead Sponsor: Shenzhen Geno-Immune Medical Institute

Target Recruit Count: 11

Registration Number: NCT04429438

Locations: 🇨🇳
Shenzhen Geno-Immune Medical Institute, Shenzhen, Guangdong, China
🇨🇳
Shenzhen Children's Hospital, Shenzhen, Guangdong, China
🇨🇳
The Seventh Affilliated Hospital, Sun Yat-Sen University, Shenzhen, Guangdong, China

4SCAR-T Therapy Post CD19-targeted Immunotherapy

Phase 1

Conditions: CD19 Negative B-cell Malignancies

Interventions: Biological: Infusion of 4SCAR-T specific to CD22/CD123/CD38/ CD10/CD20

First Posted Date: 2020-06-12

Last Posted Date: 2020-06-12

Lead Sponsor: Shenzhen Geno-Immune Medical Institute

Target Recruit Count: 100

Registration Number: NCT04430530

Locations: 🇨🇳
Shijiazhuang Zhongxi Children Hospital, Shijiazhuang, Hebei, China
🇨🇳
Shenzhen Children's Hospital, Shenzhen, Guangdong, China
🇨🇳
The Seventh Affilliated Hospital, Sun Yat-Sen University, Shenzhen, Guangdong, China

Multi-4SCAR-T Therapy Targeting Breast Cancer

Phase 1

Conditions: Breast Cancer

Interventions: Biological: 4SCAR T cells

First Posted Date: 2020-06-12

Last Posted Date: 2020-06-12

Lead Sponsor: Shenzhen Geno-Immune Medical Institute

Target Recruit Count: 100

Registration Number: NCT04430595

Locations: 🇨🇳
The Seventh Affilliated Hospital, Sun Yat-Sen University, Shenzhen, Guangdong, China

4SCAR-CD44v6 T Cell Therapy Targeting Cancer

Phase 1

Conditions: Cancers Which Are CD44v6 Positive

Interventions: Biological: CD44v6-specific CAR gene-engineered T cells

First Posted Date: 2020-06-11

Last Posted Date: 2020-06-11

Lead Sponsor: Shenzhen Geno-Immune Medical Institute

Target Recruit Count: 100

Registration Number: NCT04427449

Locations: 🇨🇳
Shenzhen Children's Hospital, Shenzhen, Guangdong, China
🇨🇳
Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China
🇨🇳
The Seventh Affilliated Hospital, Sun Yat-Sen University, Shenzhen, Guangdong, China

and more 1 locations

Safety and Immunity of Covid-19 aAPC Vaccine

Phase 1

Recruiting

Conditions: Treat and Prevent Covid-19 Infection

Interventions: Biological: Pathogen-specific aAPC

First Posted Date: 2020-03-09

Last Posted Date: 2020-03-09

Lead Sponsor: Shenzhen Geno-Immune Medical Institute

Target Recruit Count: 100

Registration Number: NCT04299724

Locations: 🇨🇳
Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China

Immunity and Safety of Covid-19 Synthetic Minigene Vaccine

Phase 1

Recruiting

Conditions: Pathogen Infection Covid-19 Infection

Interventions: Biological: Injection and infusion of LV-SMENP-DC vaccine and antigen-specific CTLs

First Posted Date: 2020-02-19

Last Posted Date: 2020-03-19

Lead Sponsor: Shenzhen Geno-Immune Medical Institute

Target Recruit Count: 100

Registration Number: NCT04276896

Locations: 🇨🇳
Shenzhen Second People's Hospital, Shenzhen, Guangdong, China
🇨🇳
Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China
🇨🇳
Shenzhen Third People's Hospital, Shenzhen, Guangdong, China

Immunotherapy Based on Antigen-specific Immune Effector Cells Targeting Neurofibromatosis or Schwannomatosis

Phase 1

Conditions: Cancer

Interventions: Biological: Antigen-specific T cells CART/CTL and DCvac

First Posted Date: 2019-09-11

Last Posted Date: 2020-06-12

Lead Sponsor: Shenzhen Geno-Immune Medical Institute

Target Recruit Count: 100

Registration Number: NCT04085159

Locations: 🇨🇳
Shenzhen Children's Hospital, Shenzhen, Guangdong, China
🇨🇳
Department of Neurosurgery, Shenzhen Hospital, Southern Medical University, Shenzhen, Guangdong, China
🇨🇳
Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China

Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies

Phase 1

Conditions: T-cell Acute Lymphoblastic Lymphoma
Acute Myeloid Leukemia
T-cell Acute Lymphoblastic Leukemia
NK Cell Lymphoma

Interventions: Biological: CD7-specific CAR gene-engineered T cells

First Posted Date: 2019-07-26

Last Posted Date: 2019-09-19

Lead Sponsor: Shenzhen Geno-Immune Medical Institute

Target Recruit Count: 30

Registration Number: NCT04033302

Locations: 🇨🇳
Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy